All News
Filter News
Found 4,569 articles
-
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
11/10/2022
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the third quarter ended September 30, 2022.
-
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
11/10/2022
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, reported financial results and business highlights for the third quarter ended September 30, 2022.
-
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
11/10/2022
Sigilon Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 as well as certain other business highlights.
-
Von Willebrand Disease Treatment Market Size to Reach US$ 905 Million by 2030
11/10/2022
The von willebrand disease treatment market size is predicted to reach US$ 905 million by 2030 from US$ 502.88 million in 2021, expanding growth at a CAGR of 6.1% from 2021 to 2030.
-
Microcarriers Market Size, Share | Report 2022-2030
11/10/2022
According to Latest Report Study, the global microcarriers market was valued at USD 1.27 billion in 2021 and it is predicted to surpass around USD 3.32 billion by 2030 with a CAGR of 11.27% from 2022 to 2030.
-
Freeline to Present at the Stifel 2022 Healthcare Conference
11/9/2022
Freeline Therapeutics Holdings plc announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.
-
A request for additional data may cause a 3-month delay for potential approval of BioMarin Pharmaceutical’s hemophilia A gene therapy.
-
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
11/8/2022
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of John F. Neylan, III, MD, as Executive Vice President, Chief Medical Officer, effective today.
-
Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022
11/8/2022
Medexus Pharmaceuticals announced its operating and financial results and provided a business update for the company’s second fiscal quarter ended September 30, 2022.
-
VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team
11/8/2022
VectorY Therapeutics announces the appointment of Sander van Deventer, co-founder and formerly Chief Technology Officer, as Chief Executive Officer.
-
BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
11/7/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today a progress update on its Biologics License Application (BLA) for valoctocogene roxaparvovec AAV gene therapy for adults with severe Hemophilia A that is currently under review by the U.S. Food and Drug Administration (FDA).
-
Sernova to Participate in the Stifel Healthcare 2022 Conference
11/4/2022
Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced it will be presenting at the upcoming Stifel Healthcare Conference being held in-person in New York, NY on November 15-16, 2022.
-
Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes
11/3/2022
Sernova Corp. is pleased to announce, in conjunction with the advancement of its ongoing Phase 1/2 clinical trial of the Sernova Cell Pouch System™ for patients with type 1 diabetes who suffer from hypoglycemia unawareness, the approval of a protocol amendment by the University of Chicago Institutional Review Board and no objections from FDA.
-
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
11/3/2022
Generation Bio Co., a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results.
-
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
11/3/2022
Genentech, a member of the Roche Group, announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022.
-
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 03, 2022
11/3/2022
Freeline Therapeutics Holdings plc announced that on October 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 75,500 of the Company’s ordinary shares.
-
Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta's SRP-9001 gene therapy in DMD in 2023
11/3/2022
Hansa Biopharma AB announced that its partner Sarepta Therapeutics plans to initiate a clinical study in 2023 to evaluate imlifidase as pre-treatment in patients with Duchenne muscular dystrophy and pre-existing IgG antibodies to the adeno-associated viral vector rh74 to enable safe and effective dosing with SRP-9001.
-
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
11/3/2022
Centessa Pharmaceuticals plc, announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension of AP-0101, a Phase 2a study of SerpinPC for the treatment of hemophilia, has been accepted for oral presentation at the 64th American Society of Hematology Annual Meeting, to be held in New Orleans, LA, from December 10 - 13, 2022.
-
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
11/3/2022
Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that preclinical data from its P-FVIII-101 program, partnered with Takeda, has been selected for an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, being held in New Orleans and virtually December 10–13, 2022.
-
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
11/3/2022
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.